Evidence map›Paper›PMID 40535006›Full record

ArticleFrontiers in microbiology2025

Superior diagnostic performance of Grocott methenamine silver staining in pulmonary cryptococcosis: a multicenter, large-sample cohort study.

Suijing Wang, Jieyi Lai, Chengyou Zheng, Pengfei Yang, Zhengyi Zhou, Haibo Wu, Mayan Huang, Xinke Zhang, Yongbo Xiao, Jierong Chen and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Suijing Wang *State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Jieyi Lai *State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Chengyou Zheng *State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Pengfei Yang *Department of Pathology, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Zhengyi ZhouState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Haibo WuState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Mayan HuangState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Xinke ZhangState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Yongbo XiaoState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Jierong ChenState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Chao MaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Keming ChenState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
Liyan LinClinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, China.
Huanyu LiuDepartment of Pathology, Peking University Shenzhen Hospital, Shenzhen, China.
Yubo CaiDepartment of Pathology, Jiangmen Central Hospital, Jiangmen, China.
Xiaolei XueDepartment of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Zizi LiDepartment of Pathology, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Jiewei ChenState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: In the histopathological diagnosis of pulmonary fungal infections, particularly pulmonary cryptococcosis, the diagnostic performance of different staining techniques varies significantly, often confounding pathologists. This study aims to systematically analyze Grocott methenamine silver (GMS), periodic acid-Schiff (PAS), and alcian blue (AB) staining methods to establish evidence-based diagnostic criteria. Methods: We incorporated histopathological data from 790 cases of pulmonary cryptococcosis that were definitively diagnosed in six tertiary hospitals. Multidimensional statistical analyses were performed to evaluate the performance of GMS, PAS, and AB staining methods. Results: GMS staining had a 100% positive diagnostic rate among all cohorts, which was significantly higher than that of PAS staining (93.7%, Conclusion: GMS staining is the best method for diagnosing pulmonary cryptococcosis because of its high sensitivity and excellent visualization capabilities. Using GMS alone can meet the requirements for diagnostic accuracy, and we recommend GMS as the gold standard for histopathological confirmation of pulmonary cryptococcosis.

Indexed as

ABGMShistologyPASpulmonary cryptococcosis

Identifiers

PMID40535006
PMCPMC12174090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.